<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-66734</identifier>
<setSpec>1695-4033</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:description xml:lang="en">Haemophagocytic syndrome is a disease diagnosed according to clinical and analytical criteria, related to many infectious diseases. It is exceptionally described in patients infected with Leishmania. Visceral leishmaniasis is an uncommon disease in our country except in some areas where it is endemic. Its diagnosis is sometimes difficult and the use of other methods currently available is needed. Haemophagocytic syndrome treatment is based on established chemotherapy protocols, but when it is secondary to Visceral Leishmaniasis, it may be an exception, since the abnormalities can be resolved by treatment of the infection itself. This treatment has improved recently as Liposomal Amphotericin B has replaced classic antimonials, being more beneficial due to less adverse effects and a shorter treatment time (AU)</dc:description>
<dc:creator>Carrascosa Romero, M. C</dc:creator>
<dc:creator>Lillo Lillo, M</dc:creator>
<dc:creator>García Villaescusa, L</dc:creator>
<dc:creator>García Mialdea, O</dc:creator>
<dc:creator>Sotoca Fernández, J. V</dc:creator>
<dc:creator>Tébar Gil, R</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">El síndrome hemofagocítico es una enfermedad diagnosticada basándose en criterios clínicos y analíticos, relacionada con numerosas entidades infecciosas. De forma excepcional se ha descrito en pacientes infectados con el parásito Leishmania. La leishmaniasis visceral es una patología infrecuente en nuestro país, salvo en zonas concretas donde es endémica. Su diagnóstico en ocasiones es difícil y hay que recurrir a varios de los métodos actualmente disponibles. El tratamiento del síndrome hemofagocítico se fundamenta en pautas quimioterápicas protocolizadas, aunque puede representar una excepción cuando es secundario a la leishmaniasis visceral, ya que el tratamiento antiinfeccioso suele resolver las alteraciones por sí mismo. Dicha terapia ha evolucionado en los últimos tiempos al sustituir la anfotericina B liposomal a las pautas clásicas con antimoniales y logrando beneficios por sus menores efectos secundarios y por acortar el tiempo de tratamiento (AU)</dc:description>
<dc:source>An Pediatr (Barc);69(1): 46-48, jul. 2008. tab</dc:source>
<dc:identifier>ibc-66734</dc:identifier>
<dc:subject>^d7399</dc:subject>
<dc:subject>^d8075^s22053</dc:subject>
<dc:subject>^d32924^s22052</dc:subject>
<dc:subject>^d11812</dc:subject>
<dc:subject>^d27249^s22045</dc:subject>
<dc:subject>^d308^s22073</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d24714^s22012</dc:subject>
<dc:subject>^d755^s22012</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d24714^s22016</dc:subject>
<dc:subject>^d755^s22016</dc:subject>
<dc:subject>^d27953^s22073</dc:subject>
<dc:subject>^d8075^s22016</dc:subject>
<dc:subject>^d27249^s22011</dc:subject>
<dc:subject>^d8075^s22012</dc:subject>
<dc:type>article</dc:type>
<dc:date>200807</dc:date>
</metadata>
</record>
</ibecs-document>
